Tumor grade and symptoms at presentation are survival risk factors in Chinese patients with primary retroperitoneal sarcoma
- PMID: 36683651
- PMCID: PMC9844221
Tumor grade and symptoms at presentation are survival risk factors in Chinese patients with primary retroperitoneal sarcoma
Abstract
Background and aim: No cohort studies have been performed on Chinese primary retroperitoneal sarcoma (RPS) patients. Data derived from western cohort studies may not be directly superimposable on Asian counterparts. Furthermore, the risk factors for survival of RPS are currently unknown for Chinese patients. The objectives were therefore to (1) gain insight into RPS incidence and patient demographics and clinical details; (2) determine the risk factors for overall survival (OS) and disease-free survival (DFS); and (3) critically appraise the Asian cohort data in relation to information obtained in western cohort studies.
Methods: In this retrospective cohort study, the health records of patients that had been diagnosed with primary localized RPS with curative intent between 2009 and 2020 were analyzed. Cox proportional hazards analysis was conducted to evaluate the risk factors for OS and DFS.
Results: A total of 261 patients met the inclusion criteria. Ninety-six (36.8%) patients had been diagnosed with well-differentiated liposarcoma, 63 patients (24.1%) with dedifferentiated liposarcoma, 41 patients (15.7%) with leiomyosarcoma (LMS), 22 patients (8.4%) with solitary fibroma, 7 patients (2.7%) with malignant peripheral nerve sheath tumor (MPNST), and 32 patients (12.3%) with another type of RPS. The study further revealed that (1) the 5-y OS and DFS in RPS patients was 67.8% and 51.3%, respectively, with the highest OS and DFS observed in MPNST (100% and 100%, respectively) and the lowest 5-y OS and DFS attributed to LMS (42.6% and 28.9%, respectively); (2) symptoms at presentation, Federal National Cancer Center (FNCLCC) grade, and number of combined resections are independent risk factors in OS; (3) symptoms at presentation, FNCLCC grade, chemotherapy, and hospital length of stay are independent risk factors for DFS; and (4) patients at high risk (symptoms at presentation and high-grade tumors) have less than half the chance of survival at 5 y post-diagnosis than patients with a low-risk profile.
Conclusions: Symptoms at presentation constitute a risk factor for OS and DFS. When combined with tumor grade - another risk factor for both OS and DFS - patients can be classified into a high-risk and low-risk category to gauge a patient's prognosis and, accordingly, frame an optimal clinical trajectory. Moreover, the clinicopathology and overall prognosis of RPS in Asian and Western populations are comparable and hence superimposable.
Relevance for patients: The present study identifies the risk factors of survival in RPS and suggests symptoms at presentation should be considered in the preoperative consultation and added in prognostic grouping.
Keywords: Asian cohort study; Soft-tissue cancer; asymptomatic; distant metastasis; hazard ratio; local recurrence; prognosis; symptoms; univariable and multivariable analysis.
Copyright: © 2022 Author(s).
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Survival and prognostic factors of primary retroperitoneal sarcomas after surgery: a single-center experience.Langenbecks Arch Surg. 2024 Jul 15;409(1):216. doi: 10.1007/s00423-024-03405-w. Langenbecks Arch Surg. 2024. PMID: 39008130
-
Characteristics and Outcomes of Locally Recurrent Retroperitoneal Sarcoma After First Relapse in a Single Tertiary Asian Centre and Applicability of the Sarculator.Front Oncol. 2021 Nov 25;11:730292. doi: 10.3389/fonc.2021.730292. eCollection 2021. Front Oncol. 2021. PMID: 34900680 Free PMC article.
-
Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG.Clin Cancer Res. 2019 Apr 15;25(8):2664-2671. doi: 10.1158/1078-0432.CCR-18-2700. Epub 2019 Feb 5. Clin Cancer Res. 2019. PMID: 30723141
-
Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group.Ann Surg Oncol. 2022 Nov;29(12):7335-7348. doi: 10.1245/s10434-022-11864-y. Epub 2022 Jun 29. Ann Surg Oncol. 2022. PMID: 35767103 Review.
-
Contemporary reappraisal of the efficacy of adjuvant chemotherapy in resected retroperitoneal sarcoma: Evidence from a nationwide clinical oncology database and review of the literature.Surg Oncol. 2017 Jun;26(2):117-124. doi: 10.1016/j.suronc.2017.01.008. Epub 2017 Feb 2. Surg Oncol. 2017. PMID: 28577717 Review.
References
-
- Mastrangelo G, Coindre JM, Ducimetiere F, Dei Tos AP, Fadda E, Blay JY, et al. Incidence of Soft Tissue Sarcoma and Beyond:A Population-based Prospective Study in 3 European Regions. Cancer. 2012;118:5339–48. - PubMed
-
- Gronchi A, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, et al. Variability in Patterns of Recurrence after Resection of Primary Retroperitoneal Sarcoma (rps):A Report on 1007 Patients from the Multi-institutional Collaborative rps Working Group. Ann Surg. 2016;263:1002–9. - PubMed
-
- Gronchi A, Vullo Lo S, Fiore M, Mussi C, Stacchiotti S, Collini P, et al. Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients. J Clin Oncol. 2009;27:24–30. - PubMed
-
- Bonvalot S, Rivoire M, Castaing M, Stoeckle E, Le Cesne A, Blay JY, et al. Primary Retroperitoneal Sarcomas:A Multivariate Analysis of Surgical Factors Associated with Local Control. J Clin Oncol. 2009;27:31–7. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous